news
Bowel cancer medication could help combat early-onset Parkinson’s disease
People with certain forms of early-onset Parkinson’s disease could potentially benefit from taking a medication used to treat certain forms of cancer.
List view / Grid view
Hit-to-Lead
news
Charles River Laboratories and Chiesi Farmaceutici SpA Announce Extension of Integrated Respiratory Drug Discovery Program
Charles River Laboratories today announced that it has extended its longstanding, strategic, integrated drug discovery partnership with Chiesi Farmaceutici SpA in the field of respiratory disease...
news
A new role for an old immune cell may lead to novel therapies
A new study has identified a previously undescribed role for a type of unconventional T cell with the potential to be used in the development of new therapies for infection and cancer.
news
Marijuana component may help treat anxiety and substance abuse disorders
Cannabidiol shown to affect emotion and emotional memory
article
Drug Target Review – Issue #1 2017
Included in this issue: Importance of building patient trust; Vaccines & Immunology; Oncology; Assays; Biomarkers; and Antibodies...
article
Whole animal screening: back to the future
High throughput screening (HTS) has become an integral and productive part of early-stage drug discovery, delivering hits that were the starting points for hit-to-lead programmes and resulting in a number of marketed drugs. HTS can be carried out in a number of formats, ranging from simple biochemical (target-based) to whole…
news
New drug lead identified in fight against Tuberculosis
Believed by many to be a relic of past centuries, tuberculosis (TB) causes more deaths than any other infectious disease including HIV/AIDs. In 2015 there were an estimated 10.4 million new cases of TB and 1.4 million deaths from the disease.
news
New discovery to identify Huntington’s disease before symptoms appear
Early warning signs of Huntington’s disease have been uncovered in sheep carrying the human HD mutation, leading the way for new insight into this devastating illness, a new study has found.
news
Positive results for Viking’s rare diseases in vivo study
Viking Therapeutics announced positive initial results from a proof-of-concept study of VK2809 in an in vivo model of glycogen storage disease Ia (GSD Ia).
news
Wellcome Trust gives Polyphor CHF 2.3 million for antibiotic development
Polyphor has received a CHF 2.3 million award from the Wellcome Trust to advance the development of broad-spectrum, Gram-negative pre-clinical product candidates.
news
‘Love hormone’ used a drug lead for inhibiting preterm labour
A team of scientists from Austria, Australia, Denmark, England and the Czech Republic, led by Christian Gruber from the MedUni Vienna's Institute of Pharmacology, managed to isolate a neuropeptide from ants that is very similar to the human love hormone oxytocin, and the closely related hormone vasopressin.
news
Lorenz Mayr joins Drug Discovery 2017 speaker lineup
Lorenz Mayr, esteemed Vice President and Global Head of Biological Reagents and Assay Development at AstraZeneca will be joining the expert speaker lineup for the launch conference on Drug Discovery. The event takes place on 27 and 28 April 2017 in London.
news
JPND launches €23 million call for neurodegenerative disease research
Neurodegenerative diseases such as Alzheimer’s disease and Parkinson’s disease are a global health, economic and social emergency.
news
Global partnership launched to enable personalised therapies in multiple sclerosis
In this project, universities and companies across 11 European countries and the US will unite efforts to tailor the development and application of therapies to the individual MS patient.
news
Gut microbes linked to immunotherapy response in melanoma patients
7 November 2016 | By Niamh Louise Marriott, Digital Content Producer
Patients with malignant melanoma are more likely to respond to immunotherapy treatment if they had greater diversity in their gut bacteria, according to...
